CIACCIO, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 4.305
EU - Europa 2.183
AS - Asia 550
Continente sconosciuto - Info sul continente non disponibili 12
AF - Africa 9
SA - Sud America 5
OC - Oceania 4
Totale 7.068
Nazione #
US - Stati Uniti d'America 4.224
IT - Italia 561
DE - Germania 440
CN - Cina 305
SE - Svezia 301
IE - Irlanda 266
UA - Ucraina 169
GB - Regno Unito 122
CA - Canada 80
HK - Hong Kong 74
IN - India 59
DK - Danimarca 56
RU - Federazione Russa 54
AT - Austria 53
FI - Finlandia 50
FR - Francia 41
VN - Vietnam 36
BE - Belgio 23
TR - Turchia 21
NL - Olanda 20
KR - Corea 14
EU - Europa 10
IR - Iran 10
SG - Singapore 10
ES - Italia 8
ET - Etiopia 7
TW - Taiwan 6
JP - Giappone 4
MM - Myanmar 4
CH - Svizzera 3
PH - Filippine 3
PL - Polonia 3
AU - Australia 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
MD - Moldavia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
BO - Bolivia 1
BR - Brasile 1
CL - Cile 1
CO - Colombia 1
DZ - Algeria 1
EC - Ecuador 1
GR - Grecia 1
HR - Croazia 1
HU - Ungheria 1
JO - Giordania 1
LI - Liechtenstein 1
ME - Montenegro 1
MX - Messico 1
SC - Seychelles 1
TH - Thailandia 1
Totale 7.068
Città #
Ann Arbor 1.025
Woodbridge 448
Fairfield 350
Chandler 311
Houston 304
Frankfurt am Main 275
Dublin 258
Wilmington 217
Ashburn 195
Jacksonville 177
Dearborn 154
New York 135
Milan 131
Cambridge 127
Seattle 125
Princeton 104
Hong Kong 74
Nanjing 63
Altamura 53
Vienna 51
Lawrence 47
Shanghai 36
Lachine 31
Dong Ket 26
Beijing 25
Lissone 24
San Diego 23
Shenyang 20
Guangzhou 19
Nanchang 18
Brussels 16
Fremont 16
Ottawa 16
Tianjin 16
Andover 15
Helsinki 15
London 15
Pune 15
Boston 13
Jiaxing 13
Toronto 13
Boardman 11
Jinan 11
Rome 11
Hebei 10
Nürnberg 10
Zhengzhou 10
Changsha 9
Kunming 9
Mountain View 9
Ningbo 9
Bologna 8
Edmonton 8
Hangzhou 8
Bergamo 7
Montréal 7
Busto Arsizio 6
Garbagnate Milanese 6
Los Angeles 6
Manchester 6
Norwalk 6
Sacramento 6
Taizhou 6
Chicago 5
Falls Church 5
Floridia 5
Foggia 5
Valencia 5
Valmadrera 5
Bonndorf 4
Comazzo 4
Hanover 4
Indianapolis 4
Monza 4
Nottingham 4
Nutley 4
Padova 4
San Francisco 4
Seoul 4
Torino 4
Verona 4
Vigevano 4
Washington 4
Aachen 3
Copenhagen 3
Hefei 3
Hounslow 3
Huizen 3
Kiev 3
Lanzhou 3
Legnano 3
Moscow 3
Mumbai 3
Napoli 3
New Taipei 3
Newtyle 3
Pavia 3
Perugia 3
Pistoia 3
Rovato 3
Totale 5.325
Nome #
Impact of multidisciplinary team approach to liver tumors: 5-Years experience 351
Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience 323
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 277
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 212
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 209
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 185
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 182
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 171
Health Related Quality of Life in the Major Liver Conditions 169
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 169
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 167
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 166
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 164
Health related quality of life in chronic liver diseases 163
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 161
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 160
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 159
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 159
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 159
The impact of liver disease on the health-related quality of life 159
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 157
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 156
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 149
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 148
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 148
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 147
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 147
The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation 143
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 135
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 133
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 133
Management of chronic hepatitis C (Chc) genotype 1 treatment-naïve patients in an era of rising opportunities and costs: A cost-effectiveness analysis 132
Management of Chronic hepatitis C (CHC) Genotype 1 treatment-naive patients in an era of rising opportunities and costs - A cost-effectiveness analysis of treatment options 132
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 131
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 123
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 121
Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1 119
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 118
Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era 107
Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis 98
Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? 96
Sofosbuvir and ribavirinin in HCV-infected patients listed for liver transplantation: A cost-effectiveness analysis 95
Difference in health related quality of life of chronic liver diseases and general population 95
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 94
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 86
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 84
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 76
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 74
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 53
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 49
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 39
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 27
Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: A systematic review and meta-analysis 18
Totale 7.428
Categoria #
all - tutte 19.962
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.962


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019334 0 0 0 0 0 0 0 0 0 65 105 164
2019/20201.344 161 84 103 94 113 160 189 103 131 99 88 19
2020/20211.059 59 53 115 119 89 76 72 98 96 99 76 107
2021/2022771 70 87 87 85 32 57 13 53 37 65 49 136
2022/20231.344 144 446 121 111 82 170 31 82 97 9 38 13
2023/2024760 30 33 22 68 86 262 158 37 61 3 0 0
Totale 7.428